Research Studies
Study Title
Neuraltus NP001 Trial (Safety and Efficacy Study of NP001 in Patients With ALS and Systemic Inflammation)
Enrollment Status
Completed
Principal Investigators
Site-PI: Michael Benatar, MD, PhD
Study Type
Drug Trial
Goals
- This is a 6 month randomized, double-blind, placebo-controlled study of NP001 in subjects with ALS and evidence of elevated systemic inflammation.
Enrolling
ALS patients
Eligibility
Click to Expand
Study Involvement
Click to Expand
Subjects will be allocated (1:1) to NP001 and placebo.
Drug or placebo will be given by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6.
Drug or placebo will be given by intravenous administration for 5 consecutive days in Month 1 and for 3 consecutive days in Months 2 through 6.
Contact
Links
Primary Funding Source
Neuraltus Pharmaceuticals, Inc
Related Publications
Click to Expand
No items found
Related Presentations & Lectures
Click to Expand
No items found